Screening for therapeutic trials and treatment indication in clinical practice: <scp>MACK</scp>‐3, a new blood test for the diagnosis of fibrotic <scp>NASH</scp>

Abstract

The new blood test MACK-3 accurately diagnoses fibrotic NASH. This new test will facilitate patient screening and inclusion in NAFLD therapeutic trials and will enable the identification of patients who will benefit from the treatments once approved.